Rocket Pharmaceuticals (RCKT) Consolidated Net Income: 2014-2024
Historic Consolidated Net Income for Rocket Pharmaceuticals (RCKT) over the last 11 years, with Dec 2024 value amounting to -$266.8 million.
- Rocket Pharmaceuticals' Consolidated Net Income rose 24.15% to -$52.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$248.2 million, marking a year-over-year increase of 7.45%. This contributed to the annual value of -$266.8 million for FY2024, which is 4.13% down from last year.
- Rocket Pharmaceuticals' Consolidated Net Income amounted to -$266.8 million in FY2024, which was down 4.13% from -$256.2 million recorded in FY2023.
- In the past 5 years, Rocket Pharmaceuticals' Consolidated Net Income registered a high of -$139.1 million during FY2020, and its lowest value of -$266.8 million during FY2024.
- Over the past 3 years, Rocket Pharmaceuticals' median Consolidated Net Income value was -$256.2 million (recorded in 2023), while the average stood at -$248.5 million.
- Data for Rocket Pharmaceuticals' Consolidated Net Income shows a maximum YoY plummeted of 76.78% (in 2020) over the last 5 years.
- Over the past 5 years, Rocket Pharmaceuticals' Consolidated Net Income (Yearly) stood at -$139.1 million in 2020, then dropped by 20.15% to -$167.2 million in 2021, then tumbled by 33.00% to -$222.3 million in 2022, then decreased by 15.26% to -$256.2 million in 2023, then fell by 4.13% to -$266.8 million in 2024.